Teva Pharmaceutical (TEVA -0.2%) says data from its Phase III Glatiramer Acetate Low-Frequency...

Teva Pharmaceutical (TEVA -0.2%) says data from its Phase III Glatiramer Acetate Low-Frequency Administration study shows a significant reduction in annual relapse rates and number of lesions in patients with relapsing-remitting multiple sclerosis, or RRMS. Detailed study results will be presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Lyon, France on October 13.

From other sites
Comments (4)
  • FrankArabia
    , contributor
    Comments (987) | Send Message
    anybody have colour on this?
    10 Oct 2012, 02:28 PM Reply Like
  • doc47
    , contributor
    Comments (1835) | Send Message
    About how much bottom line money is potentially involved here and how long before we might see it?
    10 Oct 2012, 02:49 PM Reply Like
  • chopchop0
    , contributor
    Comments (5357) | Send Message
    There are so many reasons this stock should trade higher than it does, yet it never seems to materialize in the stock price...
    10 Oct 2012, 02:52 PM Reply Like
  • FrankArabia
    , contributor
    Comments (987) | Send Message


    a lot of PMs were burned on this one when they were willing to pay over 60 for this. now the company is stronger (at least not weaker) and you get no takers. the beauty of patience in investing is if the business does well, eventually the stock will follow. eventually can be quite awhile.
    10 Oct 2012, 10:00 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs